Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Technology
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Link to: Pipeline-Proof of Concept
Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, granted with the Orphan Drug Designation by the European Medicines Agency and the US Food and Drug Administration, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Gate2Brain obtains FDA Orphan Drug Designation for G2B-002

, ,
US FDA grants Orphan Drug Designation for G2B-002 in 2025, underscoring U.S. regulatory support for…
Read more

Validation of Gate2Brain Technology in the Transport of Antibodies to the Brain Opens the Avenue of the Next Generation of CNS Therapeutics with Improved Delivery to the Brain

,
Image: Marina Plaza Press release New research highlights how advanced peptide shuttles—the…
Read more

Clàudia Resa, G2B’s Doctoral Industrial PhD student : “I am proud have developed a new drug delivery system against childhood brain cancer”

,
Research in pediatric oncology: Clàudia Resa is the industrial doctoral student in the project between…
Read more

Imitating nature to improve health

, ,
Regenerating skin or delivering medication to specific areas of our body is now possible thanks to the…
Read more

Science or science fiction? Research that reads like something out of a book

Long before the first robot hoover existed, the laws that would shape its relationship with humans had…
Read more

Gate2brain Achieves Emerging Company Certification from Enisa

,
Gate2brain S.L. has proudly received the Emerging Company Certification issued by the Ministry of Industry…
Read more

Bioengineering the Future of Drug Delivery workshop – Porto

,
Our CEO, Meritxell Teixido, and Chemist Research Scientist Marina Plaza Garrido recently participated…
Read more

New Trends in Brain Shuttle Peptides

Year: 2025 Authors: Roger Prades, Meritxell Teixidó,  Benjamí Oller Salvia Journal:  ACS Publications Abstract The…
Read more

Gate2Brain at the 2nd Peptide-Based Therapeutics Summit | Boston

,
📅 April 1-3, 2025 📍 Boston, USA We’re excited to share that Gate2Brain will be participating…
Read more

A Site-Specific MiniAp4−Trastuzumab Conjugate Prevents Brain Metastasis

Year: 2025 Authors: Mariam Masmudi-Martín, María Perea, Meritxell Teixidó, Manuel Valiente, Ernest…
Read more
NEWS & MEDIA

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social